A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1749 details |
| Primary information | |
|---|---|
| ThPP ID | Th1180 |
| Therapeutic Peptide/Protein Name | Fibrinogen Concentrate (Human) |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | 340000 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 78.7 ± 18.13 (55.73-117.26) hours |
| Description | Fibrinogen Concentrate (Human) is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. |
| Indication/Disease | For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. |
| Pharmacodynamics | Administration of fibrinogen concentrate (human) for intravenous use to patients with congenital fibrinogen deficiency replaces the missing, or low coagulation factor. Normal levels are in the range of 200 to 450 mg/dL |
| Mechanism of Action | Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin. During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A and B (FPA and FPB, respectively).2 FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers.2 The resulting fbrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis.3 Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | AUC for dose 70 mg/Kgis 124.3 ± 24.16 (81.73-156.40) mg*hr/mL |
| Volume of Distribution | 52.7 ± 7.48 (36.22-67.67) mL/KG |
| Clearance | 0.59 ± 0.13 (0.45-0.86) mL/h/KG |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Fibrinogen Concentrate (Human); The risk or severity of adverse effects can be increased when Menadione is combined with Fibrinogen Concentrate (Human); The risk or severity of adverse effects can be increased when Phylloquinone is combined with Fibrinogen Concentrate (Human); The risk or severity of adverse effects can be increased when Tranexamic Acid is combined with Fibrinogen Concentrate (Human). |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Tachosil |
| Company | Baxter Healthcare Corporation |
| Brand Discription | Fibrinogen Concentrate (Human)/human thrombin |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physcial Appearnce | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/riastap-drug/side-effects-interactions.htm |
| PubMed ID | 18179679 |
| 3-D Structure | N.A. |